Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Cassava to stop trials of Alzheimer's drug
Cassava shares sink on plans to stop Alzheimer's drug studies
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.
Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my rating on SAVA to Sell from Strong Sell.
thedeepdive
2d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
1d
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
FierceBiotech
3d
Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...
1d
ATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
LEADERSHIP Newspaper
2d
Senate Pushes For Cassava Inclusion In Flour Production
The Nigerian Senate has advanced efforts to mandate the inclusion of cassava in flour production and its derivatives.
pharmaphorum
2d
End looms for Cassava's simufilam in Alzheimer's disease
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...
2d
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
New York
NASDAQ
Alzheimer's disease
simufilam
Feedback